Closter, NJ – According to filings with the U.S. Securities and Exchange Commission, trialmatch.me is raising $19,999,661.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Tzvia Bader played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About trialmatch.me
TrialJectory is an AI-powered decision assistance platform that democratizes access to advanced treatment information. Our AI technology matches patients with personalized advanced treatment options instantly, and provides them with expert support throughout their cancer journey. We also analyzes the patient community’s real-world data of treatments and outcomes enabling all cancer patients to receive the best of care. TrialJectory is an AI-powered decision assistance platform that democratizes access to advanced treatment information. Our AI technology matches patients with personalized advanced treatment options instantly, and provides them with expert support throughout their cancer journey. We also analyzes the patient community’s real-world data of treatments and outcomes enabling all cancer patients to receive the best of care. Our mission is to democratize access to advanced cancer treatment. We empower patients to own their cancer journey with our AI-powered decision support platform. Our SaaS intelligence platform discovers barriers between Pharma and patient to expedite time to market and reduce costs.

To learn more about trialmatch.me, visit http://www.trialjectory.com/

Contact:
Tzvia Bader, President and Chief Executive Officer
tzvia@trialjectory.com
https://www.linkedin.com/in/tzvia-bader-0689a719/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved